Hemideina has raised funds via a private placement
Hemideina has raised US$7.4 million. The capital raised will be used to fund product development in preparation for the first human studies.
Hemideina is a Melbourne-based private company that is set to disrupt the cochlear implant market through its proprietary mechanical signal processing technology, the Hera wireless implant system. The company aims to provide a paradigm shift in hearing implant performance that will lead to increased access and adoption of treatment.
Oaklins’ team in Australia acted as lead manager in this transaction. The team has assisted Hemideina with fundraising since 2018 and is proud to support them on their mission to positively impact the lives of people with severe-to-profound hearing loss.



Elizabeth Williams
CEO and co-founder, Hemideina
Sprechen Sie mit dem Deal-Team
Relevante Transaktionen
Pharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Weitere InformationenHe-Man Dual Controls has been acquired by Lagercrantz UK Limited
Lagercrantz UK Limited has acquired 100% of the shares in HM Holding Limited (He-Man Dual Controls), a leader in supplemental control systems for vehicles.
Weitere InformationenAll Glass & Windows has been recapitalized by Cross Rapids Capital
Prospect Partners has sold All Glass & Windows (AGW) to Cross Rapids Capital.
Weitere Informationen